

EXPRESS MAIL MAILING LABEL

NUMBER: **EV 318655656 US**

DATE OF DEPOSIT: April 22, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Paula S. Linkhart
Paula S. Linkhart

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Robert F. Garry
Srikanta Dash
David H. Coy
Jane A. McKeating

Group Art Unit:

Examiner:

Atty. Dkt. No.: 12920.0014.PCUS00

Serial No.:

§371 US national stage of
PCT/US2003/035666

Filed:

For: FLAVIVIRUS FUSION INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria VA, 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents C1-C3, C5, C6, and C8-12 required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. References A1, A2, C4, and C7 were previously supplied to the examiner with the International Search Report dated 18 March 2005.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement. Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Deposit Account No. 01-2508/12920.0014.PCUS00.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Patricia A. Kammerer
Reg. No. 29,775
Attorney for Assignee
THE ADMINISTRATORS OF THE
TULANE EDUCATIONAL FUND

Customer No. 23369
HOWREY SIMON ARNOLD & WHITE, LLP
2941 Fairview Park Drive, Box 7
Falls Church, VA 22042
713 787 1400 (phone)
703.336.6950 (fax)

Date: April 22, 2005

Form PTO-1449 (modified)		Atty. Docket No. 12920.0014.PCUS00	Serial No. 107532480
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Robert F. Garry; Srikanta Dash; David H. Coy; Jane A. McKeating	
		Filing Date:	Group:
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Pages 1-2	

U.S. Patent Documents (do NOT delete this heading)

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,037,348	March 14, 2000	Colacino et al.			
	A2	5,747,239	May 5, 1998	Wang et al.			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Robert F. Garry, et al., "Proteomics Computational Analysis Suggest that Hepatitis C Virus E1 and Pestivirus E2 Envelope Glycoproteins and Truncated Class II Fusion Proteins," <i>Virology</i> , 307:255-265 (2003).
	C2	Hoffman-LaRoche and Trimeris, "Roche and Trimeris Announce 24-Week Results from Second Pivotal Study of HIV Inhibitor T-20", trimeris.com/news/pr/2002/020516.html .
	C3	Richard J. Kuhn et al., "Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion", <i>Cell</i> , 108:717-725 (2002).
	C4	R.J. Medinas et al., "C-Terminal gp40 Peptide Analogs Inhibit Feline Immunodeficiency Virus: Cell Fusion and Virus Spread", <i>Journal of Virology</i> , 76(18):9079-9086 (2002).
	C5	Julien Lescar, et al., "The Fusion Glycoprotein Shell of Semliki Forest Virus: An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH", <i>Cell</i> , 105:137-148 (2001).
	C6	Tatiana Suárez, "Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role During Viral Fusion", <i>Journal of Virology</i> , 74(17):8038-8047 (2000).
	C7	M. Flint et al., "The Role of Hepatitis C Virus Glycoproteins in Infection", <i>Medical Virology</i> , 10:101-117 (2000).
	C8	Mike Flint et al., "Functional Analysis of Cell Surface-Expressed Hepatitis C Virus E2 Glycoprotein", <i>Journal of Virology</i> , 73(8):6782-6790 (1999).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 12920.0014.PCUS00	Serial No. 10/532480
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Robert F. Garry; Srikanta Dash; David H. Coy; Jane A. McKeating	
		Filing Date:	Group:
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Winfried Weissenhorn et al., "Crystal Structure of the Ebola Virus Membrane Fusion Subunit, GP2, from the Envelope Glycoprotein Ectodomain", <i>Molecular Cell</i> , 2:605-616 (1998).
	C10	Carl Wild et al., "A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion", <i>Aids Research and Human Retroviruses</i> , 9(11):1051-1053 (1993).
	C11	Carl Wild et al., "Peptides Corresponding to a Predictive α -Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection", <i>Proc. Natl. Acad. Sci. USA</i> , 91:9770-9774 (1994).
	C12	William R. Gallaher, "Detection of a Fusion Peptide Sequence in the Transmembrane Protein of Human Immunodeficiency Virus", <i>Cell</i> , 50:327-328 (1987).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)